Search results
Results from the WOW.Com Content Network
COVID-19: Merck & Co. viral RNA polymerase inhibitor Moroxydine: Influenza Nelfinavir: HIV Nirmatrelvir/ritonavir (Paxlovid) COVID-19: Pfizer: 3C-like protease inhibitor (Nirmatrelvir) / inhibition of metabolism of nirmatrelvir (ritonavir) Nevirapine: HIV non-nucleoside reverse transcriptase inhibitor: Nitazoxanide: Broad-spectrum antiviral ...
In May 2022, the FDA approved baricitinib for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). [7] [14] [15] Baricitinib is the first immunomodulatory treatment for COVID-19 to receive FDA approval. [15]
Sutimlimab, sold under the brand name Enjaymo, is a monoclonal antibody that is used to treat adults with cold agglutinin disease (CAD). [1] [3] [4] It is given by intravenous infusion. [1] Sutimlimab prevents complement-enhanced activation of autoimmune human B cells in vitro. [5]
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
In May, the U.S. Centers for Disease Control and Prevention acknowledged the reoccurrence of COVID-19 following Paxlovid and continued to recommend it for people who are at high risk of serious ...
This registry based, multi-center, multi-country data provide provisional support for the use of ECMO for COVID-19 associated acute hypoxemic respiratory failure. Given that this is a complex technology that can be resource intense, guidelines exist for the use of ECMO during the COVID-19 pandemic. [85] [86] [87]
Nirmatrelvir belongs to a family of 3C-like protease inhibitors developed in the late 2010s against feline coronavirus, while ritonavir is an antiretroviral drug developed in the 1980s and used since the 1990s to inhibit the enzyme that metabolizes other protease inhibitors.
This gene encodes complement factor B, a component of the alternative pathway of complement activation. Factor B circulates in the blood as a single chain polypeptide. Upon activation of the alternative pathway, it is cleaved by complement factor D yielding the noncatalytic chain Ba and the catalytic subunit Bb. The active subunit Bb is a ...